Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Expansion of GE Drug Market Pushes Up Nichi-iko's Sales, Profits
October 23, 2006
- R&D NEWS IN BRIEF
October 23, 2006
- BUSINESS NEWS IN BRIEF
October 23, 2006
- NEW PRODUCTS
October 23, 2006
- SEMINAR
October 23, 2006
- 21st Scientific Meeting of the International Society of Hypertension
October 23, 2006
- NEW PRODUCTS
October 23, 2006
- Iressa as a Drug for 21st Century Personalized Medicine
October 23, 2006
- Japan-US Conference on Drug Review and Safety Held in Tokyo
October 23, 2006
- 65th Annual Meeting of Japanese Cancer Association (2)－2
October 16, 2006
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
October 16, 2006
- R&D NEWS IN BRIEF
October 16, 2006
- Astellas Pharma Approves New 5-Year Management Plan
October 16, 2006
- Nipro Aims to Boost Sales of Generics to \20 Bil. by 2010
October 16, 2006
- NEW PRODUCTS Alcon Japan, Kyowa Hakko: PATANOL Ophthalmic Solution 0.1%
October 16, 2006
- GENERICS NEWS IN BRIEF Court Rules for Central Glass, Abbott Laboratories in Patent Infringement Case
October 16, 2006
- Partnerships and Alliances Key to Improving R&D Productivity: Pfizer
October 16, 2006
- MEDICAL DEVICE NEWS IN BRIEF
October 16, 2006
- IFPW's 2006 General Membership Meeting in San Francisco
October 16, 2006
- NEW PRODUCTS Kainos to Launch ADAMTS13 Research Reagent
October 16, 2006
ページ
Japan is finally launching technical discussions on its cost-effectiveness assessment (CEA) system. A health ministry-funded research group is set to…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…